Autonomous Therapeutics selected for BLUE KNIGHT, a joint initiative between BARDA (a component of the U.S. Department of Health and Human Services) and Johnson & Johnson Innovation – JLABS

“WASHINGTON, D.C., August 27, 2020 - Johnson & Johnson Innovation LLC today announced the first companies to be part of its medical countermeasure innovation collaboration called Blue Knight, a joint initiative dedicated to anticipating potential health security threats, activating the global innovation community, and amplifying scientific and technological advancements with the aim to prepare for and respond to our rapidly evolving global health environment. Blue Knight has been developed in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, and Johnson & Johnson Innovation – JLABS (JLABS), a global network of life science incubators empowering and enabling innovators to deliver potential life-enhancing health and wellness solutions to people around the globe.”

Previous
Previous

Autonomous Therapeutics chosen by BARDA to present at 2020 BARDA Industry Day

Next
Next

DARPA selects Autonomous Therapeutics to support PREventing EMerging Pathogenic Threats (PREEMPT) initiative